Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent ...

What Pfizer’s recent performance tells you right now Pfizer (PFE) has drawn fresh attention after a period in which the share ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

Pfizer beat fourth-quarter estimates as Covid sales fell, pointing to obesity trial progress and cost cuts in its post-Covid ...

Pfizer shares fell as much as 5% Tuesday morning on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and ...